Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation London, UK – 11 February 2026 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced its…
Avigen enters Collaboration with NK:IO to Advance NK Cell Therapies for Solid Tumours
London, UK – 12 September 2025 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced a preclinical research and development (R&D) collaboration with NK:IO, a biotechnology…
Avigen Joins the White City Incubator
Avigen Joins the White City Incubator We are excited to announce that Avigen has moved into the White City Incubator, marking an exciting new chapter for our company as we continue to develop and scale our platform and associated service offerings….
Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation
Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation London, UK – 1 April 2025 – Avigen (“the Company”), a privately held Contract Research Organisation spun out from Imperial College London developing advanced preclinical immunotherapy R&D services using its proprietary…
Avigen Raises £300k from SFC Capital to Launch CRO Services
Avigen Raises £300k from SFC Capital to Launch Immunotherapy CRO Services London, UK – 31 March 2025 – Avigen (“the Company”), a privately held Contract Research Organisation spun out from Imperial College London developing advanced preclinical immunotherapy R&D services using its…